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Background: In phenylketonuria (PKU), elevated blood phenylalanine (Phe) concentrations are considered to impair
transport of large neutral amino acids (LNAAs) from blood to brain. This impairment is believed to underlie
cognitive deficits in PKU via different mechanisms, including reduced cerebral protein synthesis. In this study, we
investigated the hypothesis that impaired LNAA influx relates to reduced cerebral protein synthesis.
Methods: Using positron emission tomography, L-[1-11C]-tyrosine (11C-Tyr) brain influx and incorporation into
cerebral protein were studied in 16 PKU patients (median age 24, range 16 – 47 years), most of whom were early
and continuously treated. Data were analyzed by regression analyses, using either 11C-Tyr brain influx or 11C-Tyr
cerebral protein incorporation as outcome variable. Predictor variables were baseline plasma Phe concentration, Phe
tolerance, age, and 11C-Tyr brain efflux. For the modelling of cerebral protein incorporation, 11C-Tyr brain influx was
added as a predictor variable.
Results: 11C-Tyr brain influx was inversely associated with plasma Phe concentrations (median 512, range 233 –
1362 μmol/L; delta adjusted R2=0.571, p=0.013). In addition, 11C-Tyr brain influx was positively associated with 11C-Tyr
brain efflux (delta adjusted R2=0.098, p=0.041). Cerebral protein incorporation was positively associated with 11C-Tyr
brain influx (adjusted R2=0.567, p<0.001). All additional associations between predictor and outcome variables were
statistically nonsignificant.
Conclusions: Our data favour the hypothesis that an elevated concentration of Phe in blood reduces cerebral protein
synthesis by impairing LNAA transport from blood to brain. Considering the importance of cerebral protein synthesis
for adequate brain development and functioning, our results support the notion that PKU treatment be continued in
adulthood. Future studies investigating the effects of impaired LNAA transport on cerebral protein synthesis in more
detail are indicated.
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Phenylketonuria (PKU; OMIM 261600) is an inborn error
of metabolism characterized by the inability to convert
phenylalanine (Phe) to tyrosine (Tyr), caused by the defi-
ciency of hepatic phenylalanine hydroxylase (EC 1.14.16.1).
Untreated, PKU results in markedly elevated blood Phe
concentrations, low-to-normal blood Tyr concentrations,
and severe mental retardation [1]. The cornerstone of
current treatment is reducing blood Phe concentrations,
achieved in most patients by dietary Phe restriction com-
bined with a Phe-free amino acid mixture [1]. When initi-
ated early in life and followed continuously, this treatment
prevents mental retardation [1], but mild reductions in
intelligence quotient and impaired executive functioning
remain [2-8]. Although it is clear that blood Phe concen-
trations throughout life closely relate to cognitive outcome
in PKU [1], the pathophysiological consequences of ele-
vated blood Phe concentrations are unknown [9-11].
Among others, reduced cerebral protein synthesis (CPS)
is a particularly important pathophysiological mechanism
[9-11]. CPS plays an essential role during cognitive devel-
opment [12,13], and reduced CPS results in cognitive defi-
cits in several disorders [13,14]. Our group was the first to
study CPS in PKU patients [15]. In this exploratory study,
11C-Tyr cerebral protein incorporation was analyzed in
five early and continuously treated PKU patients, showing
a tendency for reduced CPS at increasing blood Phe con-
centrations. In a follow-up paper describing sixteen pa-
tients, we showed that CPS indeed decreases significantly
with increasing blood Phe concentrations [16].
Reduced CPS in PKU is believed to result from impaired
transport of large neutral amino acids (LNAAs) across the
blood–brain barrier (BBB). These LNAAs (Phe, valine, iso-
leucine, leucine, Tyr, tryptophan, threonine, histidine, and
methionine) compete for transport by the LNAA type I
(LAT1) transporter [17-20], for which Phe has the highest
binding affinity [17-19]. Possibly, competition between
LNAAs for blood-to-brain uptake also occurs at other
transporters, such as SLCA19 and SLCA15 [21]. An ele-
vated blood Phe concentration reduces uptake of non-Phe
LNAAs from blood to brain in several fundamental studies
[17-20]. Moreover, similar findings have been obtained in
clinical studies. Reduced uptake of 75Se-selenomethionine
has been reported in nine late-treated mentally re-
tarded PKU patients with blood Phe concentrations mostly
>1000 μmol/L, compared to mentally retarded patients
without PKU [22]. More recently, Landvogt et al.
(2008) reported on the striatal decarboxylation of
6-[18F]-L-dihydroxyphenylalanine (FDOPA) in seven early
and continuously treated PKU patients, with blood Phe
concentrations between 510 and 1290 μmol/L. FDOPA
and LNAAs share the same transporter. Since arterial
FDOPA concentrations were not measured in this study,
FDOPA transport from blood to brain could not bemodelled directly. However, an indirect approach assessing
FDOPA transport, based on striatal FDOPA signal intensity
changes during the first six minutes of the study, suggested
reduced FDOPA transport from blood to brain [23].
The question arises whether impaired LNAA transport
across the BBB is associated with the decrease in CPS ob-
served in PKU patients. Thus far, no studies have simul-
taneously assessed LNAA BBB transport and CPS in PKU
patients. Accordingly, we investigate the hypothesis that
the observed CPS reduction in PKU patients is associated
with impaired LNAA BBB transport.
Patients, materials and methods
Study cohort
The study cohort is the same as that in Hoeksma et al.
(2009) [16]. Sixteen adult PKU patients (seven males; age
16 – 47 years, median age 24 years) were included. Most
patients (13/16) had been diagnosed by neonatal screening
and were continuously treated since. Three patients were
late diagnosed, one of whom was identified at 3 years of
age, after his sister was diagnosed by neonatal screening.
The other two late diagnosed patients were identified after
diagnostic work-up for developmental delay at 6 and 9
years of age, respectively.
Aimed Phe treatment ranges were 200 – 500 μmol/L for
all ages until 2002, according to Dutch national guidelines.
From 2002 onward, aimed ranges were 120 – 360 μmol/L
for patients <12 years and 120 – 600 μmol/L for pa-
tients ≥12 years [24]. Clinical severity of PKU was assessed
by Phe tolerance, which is the amount of Phe that can be
consumed daily while maintaining Phe concentrations
within treatment range. Phe tolerance varied from 11 to
32 mg/kg/day at age 5 years, corresponding to 15% – 45%
of the recommended daily protein intake for age-matched
healthy subjects. Phe tolerance in early childhood reliably
predicts Phe tolerance later in life [25].
At the time of study, all patients were non-pregnant
without pregnancy wish, and free of concomitant diseases.
The Medical Ethical Committee of the University Medical
Center Groningen approved the study design. Informed
consent was obtained in all participants.
Isotope preparation
L-Tyr was obtained from Merck (Darmstadt, Germany).
No-carrier-added L-[1-11C]-Tyr (11C-Tyr) was synthesized
via microwave-induced Bucherer-Strecker synthesis, as de-
scribed previously [26]. Next, 11C-Tyr was dissolved in a
0.9% (w/v) NaCl solution and passed through a sterile
0.22 μm Millipore filter. This process resulted in an aver-
age radiochemical yield of 800 MBq, a radiochemical pur-
ity >95%, and a specific activity >40 TBq/mmol. A dose of
400 MBq 11C-Tyr, corresponding to <10 nmol 11C-Tyr,
was administered to each patient. The effects of this dose
on Tyr metabolic fluxes are negligible [27].
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Data acquisition started after a 10 – 12 h overnight fast or
a light breakfast with a very small amount of natural pro-
tein without amino acid supplement. Arterial and venous
cannulae were inserted. A venous blood sample was taken
to determine baseline plasma Phe and Tyr concentrations.
Next, patients were positioned in the whole body PET
scanner (ECAT EXACT HR+ PET camera, Siemens/CTI,
Knoxville, TN, USA). Hereafter, 400 MBq of 11C-Tyr was
infused in 8 ml 0.9% NaCl solution, followed by 32 ml so-
lution to flush the injection line, using a programmable in-
fusion system (Medrad International, Maastricht, the
Netherlands). Total injection time was 50 s. During the
next 50 min, a dynamic PET scan was performed. The
scanner was used in two-dimensional mode, imaging 63
consecutive two-dimensional images of 128 x 128 pixels
over an axial length of 15.5 cm. The in-plane resolution of
the system was 4 – 5 mm full-width half-maximum, de-
pending on the exact position in the plane. Spatial reso-
lution was nearly isotropic in all three dimensions. The
voxel size amounted to 16.5 mm3. The system was
calibrated in absolute terms and cross-calibrated with an
automated gamma well-counter (LKB Wallac, Turku,
Finland). Throughout the scanning procedure, nineteen
arterial blood samples were taken to measure plasma 11C-
Tyr concentrations, as described by Willemsen et al.
(1995) [27]: one sample every 10 s during the first minute
after injection, one sample every 30 s during the next 4
minutes, and one sample at 10, 15, 20, 30, and 40 min. For
each patient, plasma 11CO2 and
11C-protein concentra-
tions were determined in nine samples, obtained at 0.5, 1,
2.5, 5, 10, 15, 20, 30, and 40 min after injection.
Biochemical analyses
After baseline arterial blood collection, samples were
centrifuged at 2000 g x 5 min at 4 °C, and plasma was
transferred to a clean tube. Arterial plasma Phe concentra-
tions were measured using the AccQ Tag® method (Waters
BV, Breda, the Netherlands). Arterial plasma Tyr concen-
trations were measured by high-performance liquidFigure 1 Three-compartment model of 11C fluxes, adapted from Wille
11C transport to compartment A from compartment B. Compartment 1: blo
brain 11C-protein, i.e. 11C-Tyr incorporated into cerebral protein.chromatography with post-column ninhydrin derivatiza-
tion on a Biochrome 20 amino acid analyzer (Pharmacia,
Roosendaal, the Netherlands). Arterial plasma 11C radio-
activity was determined with a calibrated and automated
gamma well-counter. Quantification of 11C-Tyr, 11C-pro-
tein, and 11CO2 was performed as described by Willemsen
et al. (1995) [27]. Plasma 11C measurements were corrected
for radioactive decay (t1/2=20.4 min) during sample
manipulation.
Modelling of 11C-Tyr fluxes
A three-compartment model was used to calculate 11C-
Tyr fluxes (Figure 1), adapted from the five-compartment
kinetic model described by Willemsen et al. (1995) [27].
This modification increases the accuracy of rate constant
determination. The following three compartments were
defined: (1) a blood compartment of free 11C-Tyr, (2) a
brain compartment of free 11C-Tyr, and (3) a brain com-
partment of 11C-protein. With these three compartments,
the following rate constants were defined: k2,1, describing
the transport of free 11C-Tyr from blood to brain; k3,2, de-
scribing the incorporation of 11C-Tyr into 11C-protein in
the brain; k2,3, describing the release of
11C-Tyr from 11C-
protein in the brain; k1,2, describing the efflux of free
11C-
Tyr from brain to blood.
This model was based on results obtained in animal
studies, which indicate that certain metabolic 11C-Tyr
pathways can be ignored within the time frame of our
study [26,28]. 11C-Tyr can be metabolized to 11C-protein,
11C-3,4-dihydroxyphenylalanine (11C-DOPA), 11C-p-hy-
droxyphenylpyruvic acid (11C-HPPA), and 11C-p-hydroxy
phenyllactic acid (11C-HPLA). 11C-HPLA can be metabo-
lized to 11CO2 and next H
11CO3
-. Previous work on 14C-
Tyr in rats has shown that 60 min after injection, the
major metabolic pathway of 14C-Tyr is incorporation into
14C-protein [26]. In addition, the cerebral amount of 14C
incorporated into non-protein metabolites, including 14C-
DOPA, was <4% of the total cerebral amount of 14C [26].
Similarly, the amounts of brain 14CO2 and H
14CO3
- were
negligible [26]. In line with these results, Cumming et al.msen et al. (1995). Each rate constant kA,B reflects the unidirectional
od free 11C-Tyr; compartment 2: brain free 11C-Tyr; compartment 3:
Figure 2 Regions of interest for 11C compartment and rate
constant modelling. Upper left: right temporal region, upper right:
left temporal region, bottom: occipital region.
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lized into 3H-protein rather than 3H-DOPA [28]. Another
study investigating CPS by 11C-leucine incorporation [29]
showed that within a time frame of 110 min, the contribu-
tion of ‘recycled’ 11C-leucine (i.e. leucine derived from
proteolysis of 11C-protein reincorporated to 11C-protein)
to the 11C-leucine incorporation rate is negligible.
Based on these studies, we made the following assump-
tions regarding the three-compartment model. First,
11C-Tyr is mainly metabolized to 11C-protein, and the
contribution of brain non-protein 11C-metabolites (11C-
DOPA, 11C-HPPA, 11C-HPLA, 11CO2, and H
11CO3
-) to
total brain radiation is negligible within the time frame of
our study. Second, the contribution of 11C in the cerebral
vasculature to brain 11C signal equals ~2.5% of total brain
11C radiation. Third, the effluxes of 11C-protein, 11CO2,
and H11CO3
- from brain to blood, as well as k2,3, can be
neglected within the time frame studied.
For the purposes of this study, k2,1 was considered to re-
flect transport of non-labelled LNAAs across the BBB,
and k3,2 was considered to reflect CPS. Therefore, the pri-
mary parameters of interest in our study were k2,1 (the
transport of 11C-Tyr from blood to brain) and k3,2 (the in-
corporation of brain 11C-Tyr into brain 11C-protein). Of
note, 11C-Tyr incorporation into 11C-protein is not identi-
cal to net CPS, nor does it necessarily reflect incorpor-
ation of non-labelled, non-Tyr amino acids [27]. Both
outcome parameters were assessed in three regions of
interest (ROIs), as described by Hawkins et al. (1989) [29]
and shown in Figure 2. This regional approach was chosen
because compartment analysis cannot be performed on a
pixel-by-pixel basis, due to the stochastic variation in
radioactivity data [27]. Thus, the compartment model was
fitted to the 11C radioactivity signal per ROI per sampling
time point (Ctis(t)), and to the arterial
11C-Tyr plasma
radioactivity signal at each time point (Cpl(t)), using
the MATLAB software package (MATLAB version 5,
MathWorks Inc., Natick, MA, USA).
Statistical analyses
Testing for normality and homogeneity of variances was
done using the Shapiro-Wilk test and Levene’s test,
respectively. Normally distributed variables with homo-
geneous variances are reported as mean ± SD. Non-
normally distributed variables and/or variables with
inhomogeneous variances are given as range with median
in parentheses.
Prior to multivariate analyses, multicollinearity was
assessed by correlation analyses of predictor variables. Cor-
relation coefficients |r| >0.80 were considered to reflect
statistically relevant multicollinearity. For normally distrib-
uted variables with homogeneous variances, Pearson’s cor-
relation test was used. Otherwise, correlation testing was
done by Spearman’s rank correlation test. Multiple linearregression analyses were done using a stepwise approach,
with either k2,1 or k3,2 as outcome variables. For both out-
come variables, baseline plasma Phe, Phe tolerance, age,
and k1,2 were used as predictor variables. For the k3,2 mul-
tiple regression analysis, k2,1 was additionally selected as a
predictor variable. Baseline non-labelled plasma Tyr con-
centration was excluded as a predictor variable in all
models, as it was involved in calculating 11C-Tyr fluxes and
would thus by definition show high r-values.
Following multiple regression analyses, the assumptions
of homoscedasticity, independence of errors, normality of
error distribution, and linearity were evaluated. In addition,
the presence of multicollinearity was again assessed, by
analyzing variance inflation factor (VIF) and tolerance
values. Statistical analyses were done using SPSS (Windows
version 20, SPSS, Chicago, IL, USA). A two-sided p-value
<0.05 was considered to be statistically significant.
Results
Patient characteristics and 11C-Tyr fluxes
Individual patient data are presented in Table 1. Baseline
venous plasma Phe concentrations ranged from 233 to
1362 μmol/L (512 μmol/L). Five of the sixteen subjects
Table 1 Study cohort characteristics




1 16 28 233 66 0.055 1.06 0.073
2 23 11 358 37 0.037 0.48 0.064
3 23 12 361 32 0.046 0.71 0.077
4 24 16 373 35 0.041 0.46 0.070
5 26 31 375 47 0.031 0.50 0.052
6 25 27 405 49 0.031 0.47 0.069
7 23 20 411 87 0.037 0.70 0.072
8 21 18 477 31 0.034 0.42 0.061
9 22 32 546 42 0.033 0.54 0.057
10 25 13 565 76 0.028 0.78 0.047
11 20 19 586 38 0.039 0.55 0.085
12 24 17 632 61 0.023 0.50 0.055
13 21 15 805 35 0.027 0.36 0.066
14 27 23 825 49 0.021 0.32 0.060
15 47 14 1078 33 0.019 0.21 0.029
16 33 12 1362 37 0.021 0.34 0.049
Phe tolerance values were obtained at age 5 years. Patients 15 and 16 were treated from 6 and 9 years of age onward, respectively. In these patients, Phe
tolerance was determined 6 months after treatment start. Phenylalanine and tyrosine plasma concentrations shown are baseline values. a 11C-Tyr transport from
blood to brain (ml plasma/g brain tissue/min). b 11C-Tyr cerebral protein incorporation (nmol/g brain tissue/min). c 11C-Tyr transport from brain to blood
(ml plasma/g brain tissue/min).
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upper limit (i.e. 600 μmol/L). Baseline venous plasma Tyr
concentrations ranged from 31 to 87 μmol/L (40 μmol/L).
Mean rate of clearance of free 11C-Tyr by transport from
blood to brain (k2,1) was 0.033 ± 0.010 ml plasma/g brain
tissue/min. Mean 11C-Tyr incorporation into cerebral
protein (k3,2) was 0.53 ± 0.21 nmol/g brain tissue/min.
Mean rate of clearance of free 11C-Tyr by transport from
brain to blood (k1,2) was 0.062 ± 0.014 ml plasma/g brain
tissue/min.11C-Tyr transport from blood to brain
The stepwise multiple linear regression with 11C-Tyr
transport from blood to brain as dependent variable
resulted in a significant model (adjusted R2=0.669,
F=16.182, p<0.001). Parameters of this model are summa-
rized in Table 2. In this model, baseline Phe concentration
and k1,2 were significant predictor variables for
11C-TyrTable 2 Multiple linear regression modelling for 11C-Tyr
transport from blood to brain
B SE B β Adjusted
R2 change
p
Baseline Phe −1.728 * 10-5 0.000 −0.529 0.571 0.013
k1,2 0.301 0.132 0.417 0.098 0.041
Constant 0.024 0.011 n.a. n.a. 0.041
Multiple regression model with 11C-Tyr transport from blood to brain as
outcome variable, using baseline plasma Phe, Phe tolerance, age, and k1,2 as
predictor variables. Only statistically significant predictor variables are shown.
k1,2:
11C-Tyr transport from brain to blood. SE: standard error.transport from blood to brain (Δ adjusted R2=0.571,
p=0.013; Δ adjusted R2=0.098, p=0.041, respectively). 11C-
Tyr transport from blood to brain showed a negative par-
tial correlation with baseline Phe concentration, indicating
that at increasing baseline Phe concentrations, 11C-Tyr in-
flux to brain is decreased. 11C-Tyr influx to brain showed
a positive partial correlation with k1,2, indicating that with
increasing efflux of 11C-Tyr from brain to blood, 11C-Tyr
transport from blood to brain increases. Statistical ana-
lyses to verify the assumptions for multiple linear regres-
sion showed that the assumptions of homoscedasticity,
independent errors, normality of error distribution, and
linearity had been met. Correlation coefficients between
predictor variables, as well as VIF and tolerance values,
were consistent with no multicollinearity. Figure 3 shows
the relation between 11C-Tyr transport from blood to
brain and plasma Phe concentration .11C-Tyr cerebral protein incorporation
The stepwise multiple linear regression with 11C-Tyr cere-
bral protein incorporation as dependent variable resulted
in a significant model (adjusted R2=0.567, F=20.642,
p<0.001), with only 11C-Tyr transport from blood to brain
as a significant predictor variable. Parameters of this
model are summarized in Table 3. 11C-Tyr cerebral pro-
tein incorporation showed a positive partial correlation
with 11C-Tyr transport from blood to brain. Thus, lower
11C-Tyr influx values were associated with lower 11C-Tyr
cerebral incorporation values. Following the main analysis,











































Figure 3 Relation between 11C-Tyr transport from blood to brain and plasma phenylalanine concentration.
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tions for multiple linear regression. These analyses showed
that the assumptions of homoscedasticity, independent er-
rors, normality of error distribution, and linearity had
been met. Correlation coefficients between predictor vari-
ables, as well as VIF and tolerance values, were consistent
with no multicollinearity. Figure 4 shows the relation be-
tween 11C-Tyr cerebral protein incorporation and 11C-Tyr
transport from blood to brain.Discussion
This study is the first to simultaneously investigate
LNAA transport from blood to brain and CPS in PKU
patients. Our work can be summarized in two main find-
ings. First, increased blood Phe concentrations are
strongly associated with reduced 11C-Tyr transport from
blood to brain. Second, reduced 11C-Tyr transport from
blood to brain is strongly associated with reduced 11C-
Tyr cerebral protein incorporation. Before discussing the
results of this study, we will first address the strengths
and limitations of our approach.
11C-Tyr transport from blood to brain and 11C-Tyr cere-
bral protein incorporation were calculated using a three-
compartment model, adapted from [27]. This approachTable 3 Multiple linear regression modelling for 11C-Tyr
cerebral protein incorporation
B SE B β Adjusted R2 change p
k2,1 16.303 3.588 0.772 0.567 <0.001
Constant −0.008 0.122 n.a. n.a. 0.949
Multiple regression model with 11C-Tyr cerebral protein incorporation as
outcome variable, using baseline plasma Phe, Phe tolerance, age, k1,2 and k2,1
as predictor variables. Only statistically significant predictor variables are
shown. k2,1:
11C-Tyr transport from blood to brain. SE: standard error.differs from that in our previous study [16], which only
allowed for quantification of CPS. Our current model al-
lows for the assessment of multiple compartments and
11C-Tyr fluxes between these compartments. As outlined
above, this three-compartment model is based on results
found in animal studies [26,28,29]. It should be noted that
these findings have not been validated in humans.
The assumptions for performing multiple linear regres-
sion analyses were met, indicating that our conclusions can
be generalized to other PKU patient cohorts. Still, for ex-
tensive statistical analyses such as regression modelling
with four to five predictor variables, a cohort size of sixteen
subjects is relatively small. This relatively small sample size
may have reduced the power of the regression analyses in
our study. Although the nonsignificant predictor variables
in our study may correlate to some extent with their corre-
sponding outcome variables, these correlations should be
weaker that the currently observed correlations.
In order to acquire reliable measurements, a steady state
condition in each patient was required. To obtain such a
condition, patients fasted prior to the study and refrained
from taking amino acid formula. After an overnight fast,
some patients consumed a light breakfast with a very lim-
ited amount of Phe, whereas other patients remained
fasted. We consider the influence of the light breakfast to
be minimal, as we previously showed that such a breakfast
does neither affect blood Phe nor blood Tyr concentra-
tions [30]. Similarly, one could hypothesize that ceasing
amino acid formula intake could have affected blood Phe
and Tyr concentrations during the study period. First, in-
take of amino acid formula could reduce Phe uptake at
the gut-blood barrier, thus reducing blood Phe concentra-
tions. Second, formula intake could increase blood Tyr
concentrations. Whether these effects would in turn influ-
ence 11C-Tyr fluxes remains to be investigated.
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Figure 4 Relation between 11C-Tyr cerebral protein incorporation and 11C-Tyr transport from blood to brain.
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Phe and 11C-Tyr efflux from brain to blood were found to
be significant predictor variables. Of these two variables,
baseline Phe showed the strongest association with 11C-
Tyr influx. This strong association supports the concept
that increased blood Phe concentrations reduce binding of
blood non-Phe large neutral amino acids to the LAT1
transporter, thus reducing brain influx of these amino
acids. The observed relationship between increased blood
Phe concentrations and reduced 11C-Tyr influx could not
have been biased by in vivo tyrosine synthesis, as flux ana-
lyses were performed for 11C-Tyr rather than Tyr, and a
standardized amount of 11C-Tyr was administered to each
patient. The significant association between 11C-Tyr influx
and 11C-Tyr efflux may be explained as follows. Similar to
brain influx, brain efflux of large neutral amino acids is at
least partly mediated by the LAT1 transporter [31]. In
addition to LAT1 [32], other amino acid transport systems
exist at the abluminal membrane of BBB endothelial cells,
which similarly transport LNAAs in a competitive manner
[33]. These transport systems may thus complement
LAT1 in mediating LNAA efflux from brain to blood
[31,33]. Therefore, increased brain Phe concentrations
could competitively reduce 11C-Tyr efflux via several
transporters, including LAT1. Such increased brain Phe
concentrations likely occur at increased blood Phe con-
centrations, which in turn are significantly associated with
reduced 11C-Tyr influx. Thus, reduced 11C-Tyr influx may
be associated with reduced 11C-Tyr efflux. In the 11C-Tyr
cerebral protein incorporation regression model, 11C-Tyr
transport from blood to brain was found to be a signifi-
cant predictor variable, whereas blood Phe concentration
was not. Blood Phe concentration explained 57% of the
observed variance in 11C-Tyr transport from blood tobrain. Thus, 43% of the observed variance could not be
prediced by blood Phe concentration. This relatively large
variance unexplained by blood Phe concentration may
clarify why blood Phe concentration did not independ-
ently predict 11C-Tyr cerebral protein incorporation.
Only two subjects had blood Phe concentrations outside
the 360 – 1000 μmol/L range. On the one side, this result
could limit the predictive value of our models for patients
with blood Phe concentrations outside the studied range.
Therefore, to further validate our conclusions, more pa-
tients with Phe concentrations <360 μmol/L and >1000
μmol/L at the time of study (presumably associated with
relatively high and low values for LNAA BBB influx and
CPS) should be investigated. On the other side, the blood
Phe range studied offers new insights. First, contrary to
previous reports, our dataset systematically studies LNAA
BBB transport and CPS in PKU patients with blood Phe
concentrations <1000 μmol/L. In the study of Oldendorf
et al. [22], only two patients had blood Phe concentrations
below this value. In the study of Landvogt et al. [23], indi-
vidual blood Phe concentrations are not presented. How-
ever, it can be deduced from these data that at most three
patients had blood concentrations <1000 μmol/L. Second,
the blood Phe range in our study includes 600 μmol/L,
the currently aimed treatment maximum for adults. Even
in patients with blood Phe concentrations below this
current treatment maximum, 11C-Tyr transport from
blood to brain was decreased compared to that observed
at lower blood Phe concentrations. This finding suggests
that the current treatment maximum may have to be
lowered in order to obtain optimal cognitive development.
The results presented in this study may have both fun-
damental and clinical implications. Regarding the funda-
mental relevance, reduced CPS may be one of the main
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tardation. CPS is involved in many processes during brain
development, including neuronal differentiation, matur-
ation, migration, synaptic plasticity, and the formation of
functional networks [12,13]. Thus, reduced CPS may
negatively affect cognition via many mechanisms. Indeed,
in inherited mental retardation diseases other than PKU,
reduced CPS has been described [13,34]. Clinically, our
data underline the importance of continuing PKU treat-
ment after early adulthood. CPS-dependent developmen-
tal processes continue into the third decade [35,36], and
CPS-dependent synaptic plasticity occurs lifelong [37].
Thus, also at adult age, reduced CPS could contribute to
impaired cerebral functioning. Finally, the observation that
both 11C-Tyr influx from blood to brain and cerebral pro-
tein incorporation are reduced in PKU patients considered
to be well-treated, justifies the development of new treat-
ments aiming to restore these abnormalities.
Follow-up studies should focus on the functional conse-
quences of reduced CPS in PKU, as well as the identifica-
tion of a safe blood Phe upper limit with regards to CPS.
Another direction for future research is to identify the
contributions of elevated brain Phe concentrations and re-
duced brain non-Phe LNAA concentrations to reduced
CPS. Combination of PET with magnetic resonance spec-
troscopy allows for investigating the association between
brain Phe concentrations and CPS.
In summary, we observed that reduced 11C-Tyr cerebral
protein incorporation in early and continuously treated
PKU patients is strongly associated with reduced 11C-Tyr
transport from blood to brain. 11C-Tyr transport from
blood to brain was significantly reduced at increasing
blood Phe concentrations. These findings support the hy-
pothesis that reduced CPS in PKU results from impaired
LNAA transport from blood to brain. Our findings may
serve as a starting point for both improving current treat-
ment practice and developing new treatment strategies, in
order to optimize cognitive outcome and quality of life in
PKU patients.
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